Cargando…

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments

SIMPLE SUMMARY: A novel challenge in cancer immunotherapy is the identification of the most potent combinations of immunomodulatory mAbs that are capable of maximizing therapeutic benefits while minimizing irAEs. We set up an in vitro system to quickly predict the efficacy and eventual cardiotoxic s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vetrei, Cinzia, Passariello, Margherita, Froechlich, Guendalina, Rapuano Lembo, Rosa, Zambrano, Nicola, De Lorenzo, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230074/ https://www.ncbi.nlm.nih.gov/pubmed/34201082 http://dx.doi.org/10.3390/cancers13122858

Ejemplares similares

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
por: Vetrei, Cinzia, et al.
Publicado: (2021)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
por: Passariello, Margherita, et al.
Publicado: (2019)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand
por: Zambrano, Nicola, et al.
Publicado: (2022)

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
por: Passariello, Margherita, et al.
Publicado: (2021)

A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab
por: Passariello, Margherita, et al.
Publicado: (2022)

Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays
por: Passariello, Margherita, et al.
Publicado: (2023)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies
por: Manna, Lorenzo, et al.
Publicado: (2023)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies
por: Sasso, Emanuele, et al.
Publicado: (2018)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
por: Liu, Jingxian, et al.
Publicado: (2019)

Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
por: Chen, Yezi, et al.
Publicado: (2022)

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
por: Li, Xiuying, et al.
Publicado: (2023)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
por: Wei, Joe Q., et al.
Publicado: (2023)

A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells
por: Sasso, Emanuele, et al.
Publicado: (2018)

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review
por: Shang, Jingyuan, et al.
Publicado: (2022)

Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis
por: Passariello, Margherita, et al.
Publicado: (2021)

Norepinephrine inhibits CD8(+) T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma
por: Geng, Qishun, et al.
Publicado: (2023)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Near‐infrared fluorescence‐labeled anti‐PD‐L1‐mAb for tumor imaging in human colorectal cancer xenografted mice
por: Zhang, Mingyu, et al.
Publicado: (2019)

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers
por: Ba, Hongping, et al.
Publicado: (2023)

The immunomodulatory effect of microglia on ECM neuroinflammation via the PD‐1/PD‐L1 pathway
por: Shen, Yan, et al.
Publicado: (2021)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
por: Passariello, Margherita, et al.
Publicado: (2019)

Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus
por: Parrington, Helen M., et al.
Publicado: (2023)

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
por: Nagato, Toshihiro, et al.
Publicado: (2014)

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs
por: Zhang, Tian, et al.
Publicado: (2023)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

The usefulness of change in CT score for evaluating the activity of Mycobacterium abscessus (Mab) pulmonary disease (Mab-PD)
por: Shinfuku, Kyota, et al.
Publicado: (2023)

Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization
por: Noy-Porat, Tal, et al.
Publicado: (2023)

Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
por: Curnock, Adam P., et al.
Publicado: (2021)

Effects of combined treatment with PD-L1 Ig and CD40L mAb on immune tolerance in the CBA/J × DBA/2 mouse model
por: Li, Guanfei, et al.
Publicado: (2020)

PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis
por: Wang, Fang, et al.
Publicado: (2022)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7b9cumahos7iv27k2c46ai9d89